Tempus AI Q3 revenue climbs 23% to $411.5M

Tempus AI (NASDAQ:TEM) reported third-quarter 2026 revenue of $411.5 million, up 23% year over year, exceeding analyst expectations and prompting higher full-year revenue guidance.

Revenue exceeded the approximately $409 million analyst consensus, while adjusted earnings per share reached $0.07 against expectations of a $0.08 loss.

The company reported a GAAP net loss of $14.9 million, compared with a $80 million loss a year earlier, while adjusted EBITDA increased to $25.6 million from $1.5 million.

Diagnostics revenue increased 20% to $303.5 million, supported by 32% oncology volume growth and a 300% increase in minimal residual disease testing, while Data and Applications revenue rose 33% to $108.1 million.

Tempus raised its 2026 revenue guidance to $1.60 billion–$1.605 billion, representing approximately 25% annual growth, and maintained adjusted EBITDA guidance of approximately $65 million.

Following the announcement, Tempus shares rose approximately 4%, according to market reports.

Year-to-date data licensing bookings exceeded $550 million, supported by agreements involving Bristol Myers Squibb, Merck and Moderna, while the company continued expanding its diagnostics and healthcare data businesses.

Tempus develops AI-enabled precision medicine solutions using clinical, genomic and molecular data to support healthcare providers, pharmaceutical companies and drug development research.